Skip to main content
Premium Trial:

Request an Annual Quote

Readying to Deploy Dx Products, Rosetta Genomics' CEO Moves to US

NEW YORK (GenomeWeb News) - Rosetta Genomics said today that its CEO, Amir Avniel, has moved his office from the company's headquarters in Rehovot, Israel, to New York as part of a plan to expand its US operations.
 
The company said the move will "facilitate the expected launch of Rosetta Genomics' first products, growth through partnerships and collaborations, as well as corporate operations in the US."
 
"As we move closer to the planned launch of our first diagnostic products in 2008 and to ensure the growth and expansion of our technologies, it is critical to have our senior executives based in the US," said Yoav Chelouche, Rosetta Genomics' chairman of the board of directors.
 
Michael French, president of the company’s US subsidiary, Rosetta Genomics Inc., has departed the company. Avniel will assume French's responsibilities, the company said.

The Scan

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.

Study Highlights Pitfall of Large Gene Panels in Clinical Genomic Analysis

An analysis in Genetics in Medicine finds that as gene panels get larger, there is an increased chance of uncovering benign candidate variants.

Single-Cell Atlas of Drosophila Embryogenesis

A new paper in Science presents a single-cell atlas of fruit fly embryonic development over time.

Phage Cocktail Holds Promise for IBD

Researchers uncovered a combination phage therapy that targets Klebsiella pneumonia strains among individuals experiencing inflammatory bowel disease flare ups, as they report in Cell.